

## PERSONAL INFORMATION

**Alberto Gajofatto**

Sex Male | Date of birth 25/02/1978 | Nationality Italian

📍 University of Verona, Department of Neuroscience, Biomedicine and Movement Sciences

Piazzale L.A. Scuro 10, 37134 Verona, Italy

☎ +39 045 812 4285

✉ [alberto.gajofatto@univr.it](mailto:alberto.gajofatto@univr.it)

🌐 <http://www.dsnm.univr.it/?ent=persona&id=6421>

## PRESENT POSITION

**Sr. Assistant Professor in Neurology**

Department of Neuroscience, Biomedicine and Movement Sciences

University of Verona, Italy

**Consultant**

Neurology Unit B – Regional Multiple Sclerosis Center

Azienda Ospedaliera Universitaria Integrata Verona

## WORK EXPERIENCE

from 2013 to 2018

**Jr. Assistant Professor in Neurology**

Department of Neuroscience, Biomedicine and Movement Sciences

University of Verona, Italy

2018

**National Scientific Certification for the position of Associate Professor in Neurology**

November-December 2015

**Visiting Researcher**

Multiple Sclerosis Center, University of California, San Francisco, CA, USA

from 2012 to 2013

**Research Fellow**

Department of Neurological Sciences, University of Verona, Italy

from 2008 to 2012

**Clinical Fellow**

Policlinico G.B. Rossi, Neurology Department, Multiple Sclerosis Center, Verona, Italy

from 2006 to 2007

**Post-Doctoral Fellow**

Multiple Sclerosis Center, University of California, San Francisco, CA, USA

from 2003 to 2008

**Resident in Neurology**

Policlinico G.B. Rossi, Neurology Department, University of Verona, Italy

## EDUCATION AND TRAINING

2012

**Ph. D. Neuroscience**

University of Verona

2008

**Neurology Certification**

University of Verona

2003

**Medical Degree**

University of Verona

1997

**High School Diploma – scientific studies**

Liceo Scientifico A. Messedaglia, Verona

## PERSONAL SKILLS

Mother tongue

Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1/2	C1/2	C1/2	C1/2	C1/2
TOEIC Certificate (870/990)					
Spanish	A1/2	A1/2	A1/2	A1/2	A1/2

**Organisational / managerial skills** Member of the PhD program in Neuroscience Board of Teachers, University of Verona; 2018 –  
 Member of the School of Medicine Board of Teachers, University of Verona; 2015 –  
 Member of the School of Nursing Board of Teachers, University of Verona; 2015 –  
 Member of the Neurology Residency Program Board of Teachers, University of Verona; 2014 –

**CONCEPTION AND COORDINATION OF RESEARCH PROJECTS:**

- Relevance of anti-aquaporin 4 and anti-MOG antibodies in the diagnosis of atypical demyelinating events of the central nervous system; 2016 – ongoing
- Validation study of 2010 McDonald criteria and 2016 MAGNIMS guidelines for the diagnosis of primary progressive multiple sclerosis; 2015 – 2017
- Brain functional MRI changes in multiple sclerosis patients with spasticity; 2014 – 2016
- Correlation between cerebrospinal fluid markers of neurodegeneration and MRI measures of gray matter pathology in multiple sclerosis; 2014 – ongoing
- Clinical and cognitive evolution of multiple sclerosis with benign course: a 5-year prospective study; 2013-2014
- Natalizumab or fingolimod as second-line options for relapsing-remitting multiple sclerosis: an observational study; 2012 – 2014
- Exploratory CSF biomarkers in patients with an initial demyelinating event of the CNS; 2009 – 2012
- Predictors of recovery, symptom recurrence, conversion to multiple sclerosis and long-term disability after acute myelitis; 2007 – 2008
- Impact of switching first-line disease-modifying therapy after treatment failure in relapsing-remitting multiple sclerosis; 2006 – 2007

- Job-related skills**
- CLINICAL EXPERIENCE IN GENERAL NEUROLOGY
  - CLINICAL EXPERIENCE IN MULTIPLE SCLEROSIS AND RELATED DISORDERS
  - EXPERIENCE IN CLINICAL AND TRANSLATIONAL RESEARCH ON MULTIPLE SCLEROSIS:
    - therapeutic strategies after first-line treatment
    - CSF pathogenetic markers with potential prognostic significance
    - epidemiology
  - PARTICIPATION IN MULTICENTER STUDIES AND CLINICAL TRIALS:
    - Beta-interferon in Early relapsing-remitting multiple sclerosis Surveillance Trial – BEST (Mult Scler 2007; 13: S49)
    - GERONIMUS Study (Gruppo Emiliano-ROmagnolo Neurologi In Multiple Sclerosis) (Eur J Neurol 2009; 16, Suppl 3: 245)
      - Multicenter randomized non-inferiority trial of azathioprine vs interferon beta in RRMS – MAIN trial (Neuroepidemiology 2009; 33: 197)
      - CFTY720D2316: A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis.
      - BD0109: Relationship between IL-6 and TNF- $\alpha$  polymorphism with flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1 a im
      - CFTY720D2399: A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis
      - NGM114840: A randomized, single blind, placebo-controlled, single ascending dose/repeat dose cohort study to assess safety, tolerability, pharmacokinetics and immunogenicity of GSK1223249 in patients with relapsing forms of multiple sclerosis
      - CFTY720DIT03: An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists
      - EFC6058 – Teracles: A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta
      - Cortical pathology biomarkers for the stratification of early progressive multiple sclerosis patients; Progressive MS Alliance grant 2015
      - Epidemiology of Multiple Sclerosis in the Veneto Region network; Ricerca Sanitaria Finalizzata Regione Veneto 2015
- Computer skills**
- good command of Microsoft Office™ tools
  - good command of SPSS™
- Teaching skills**
- University of Verona School of Medicine:  
 Neurology (School of Nursing, Bolzano)  
 Neurology practice training (School of Medicine)  
 Neurological examination and clinical reasoning in neurology (Neurology Residency Program)
- Mentorship:  
 School of Medicine, University of Verona (Nursing Students, Medical Students, Residents)

## Articles in Peer-Reviewed Journals Indexed in Pubmed

1. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. *Mult Scler.* 2009; 15:50-58 (IF: 3.279; JCR 2009)
2. Gajofatto A, Monaco S, Fiorini M, Zanusso G, Vedovello M, Rossi F, Turatti M, Benedetti MD. Assessment of outcome predictors in first-ever acute myelitis: a retrospective study on 53 cases. *Arch Neurol.* 2010; 67:724-730 (IF: 7.108; JCR 2010)
3. Turatti M, Gajofatto A, Rossi F, Vedovello M, Benedetti MD. Long survival and clinical stability in Marburg's variant multiple sclerosis. *Neurol Sci.* 2010; 31:807-811 (IF: 1.220; JCR 2010)
4. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree B, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. *Plos One* 2011; 6(2):e16664 (IF: 4.092, JCR 2011)
5. Invernizzi P, Bertolasi L, Turatti M, Bianchi MR, Gajofatto A, Benedetti MD. Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. *J Neurol.* 2011; 258:1933-1939 (IF: 3.473, JCR 2011)
6. Zanusso G, Fiorini M, Ferrari S, Gajofatto A, Cagnin A, Galassi A, Richelli S, Monaco S. Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. *Int J Mol Sci.* 2011;12(9):6281-92 (IF: 2.598, JCR 2011)
7. Gajofatto A, Bongiani M, Zanusso G, Benedetti MD, Monaco S. Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? *Int J Mol Sci* 2011; 12(11):7960-70 (IF: 2.598, JCR 2011)
8. Bertolasi L, Acler M, Dall'ora E, Gajofatto A, Frasson E, Tocco P, Turri M, Ferlisi M, Fiorini M, Pimazzoni F, Squintani G, Martini M, Danzi B, Monaco S. Risk factors for post-polio syndrome among an Italian population: a case-control study. *Neurol Sci.* 2012; 33(6):1271-5 (IF: 1.412, JCR 2012)
9. Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. HCV-Related Nervous System Disorders. *Clin Dev Immunol.* 2012; 2012:236148. Epub 2012 Jul 30 (IF: 3.064, JCR 2012)
10. Gajofatto A, Benedetti MD. Prognostic factors of acute partial transverse myelitis. *Arch Neurol.* 2012; 69:1523 (IF: 7.685; JCR 2012)
11. Turatti M, Gajofatto A, Bianchi MR, Ferrari S, Monaco S, Benedetti MD. Benign course of tumour-like multiple sclerosis: report of five cases and literature review. *J Neurol Sci.* 2013; 324(1-2):156-62 (IF: 2.262; JCR 2013)
12. Gajofatto A, Stefani A, Turatti M, Bianchi MR, Gomez Lira M, Moretto G, Salviati A, Benedetti MD. Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study. *Eur J Neurol.* 2013; 20(4):697-703 (IF: 4.162; JCR 2012)
13. Bertolasi L, Frasson E, Turri M, Gajofatto A, Bordignon M, Zanolin E, Martini M, Pimazzoni F, Ferlisi M, Zanusso G, Rossi M, Monaco S. A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome. *J Neurol Sci.* 2013; 330(1-2):94-99 (IF: 2.262; JCR 2013)
14. Gajofatto A, Bongiani M, Zanusso G, Bianchi MR, Turatti M, Benedetti MD, Monaco S. Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis. *Acta Neurol Scand* 2013; 128:336-344 (IF: 2.437; JCR 2013)
15. Gajofatto A, Calabrese M, Benedetti MD, Monaco S. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. *Dis Markers* 2013;35(6):687-99 (IF: 2.174; JCR 2013)
16. Gajofatto A, Bianchi MR, Deotto L, Benedetti MD. Are Natalizumab and Fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. *Eur Neurol.* 2014;72:173-180 (IF: 1.362; JCR 2013)
17. Gajofatto A, Gobbin F, Piffer S, Calabria F, Forlivesi S, Fenzi F, Barbieri A, Lunardi C, Monaco S, Benedetti MD. Two sisters with leukoencephalopathy, hearing loss and retinopathy: a familial case of Susac's syndrome? *Br J Med Med Res.* 2014; 4(36):5818-5824
18. Calabrese M, Gajofatto A, Benedetti MD. Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy. *Expert Rev Neurother.* 2014;14(12):1417-28. (IF: 2.834; JCR 2013)
19. Calabrese M, Gajofatto A, Gobbin F, Sala F, Turri G, Richelli S, Matinella A, Oliboni ES, Benedetti MD, Monaco S. Late-onset multiple sclerosis presenting with cognitive dysfunction and cortical/infratentorial atrophy. *Mult Scler.* 2015;21(5):580-89 (IF: 4.863; JCR 2013)
20. Gandolfi M, Munari D, Geroin C, Gajofatto A, Benedetti MD, Midiri A, Carla F, Picelli A, Waldner A, Smania N. Sensory integration balance training in patients with multiple sclerosis: a randomized, controlled trial. *Mult Scler.* 2015 Oct;21(11):1453-62 (IF: 4.863; JCR 2013)

21. Martinella A, Lanzafame M, Bonometti MA, Gajofatto A, Concia E, Vento S, Monaco S, Ferrari S. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. *J Neurol*. 2015;262(5):1317-27 (IF: 3.841; JCR 2013)
22. Mattarozzi K, Casini F, Baldini M, Baldin E, Lugaresi A, Milani P, Pietrolongo E, Gajofatto A, Leone M, Riise T, Vignatelli L, D'Alessandro R, on behalf of G.E.Ro.N.I.Mu.S. group. Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure. *Health Expect*. 2015 Apr 24 [Epub ahead of print] (IF: 3.410; JCR 2014)
23. Gajofatto A, Turatti M, Bianchi MR, Forlivesi S, Gobbin F, Azzarà A, Monaco S, Benedetti MD. Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions. *Acta Neurol Scand*. 2016 Mar;133(3):183-91. Epub 2015 May 26 (IF: 2.395; JCR 2014)
24. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? *World J Clin Cases* 2015 Jul 16;3(7):545-55
25. Calabrese M, Reynolds R, Magliozzi R, Castellaro M, Morra A, Scalfari A, Farina G, Romualdi C, Gajofatto A, Pitteri M, Benedetti MD, Monaco S. Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients. *PLoS One*. 2015 Aug 12;10(8):e0135428 (IF: 3.234; JCR 2014)
26. Mariotto S, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, Gajofatto A, Monaco S. Brentuximab vedotin: axonal microtubule's Apollyon. *Blood Cancer J*. 2015 Aug 28;5:e343 (IF: 3.467; JCR 2014)
27. Monaco S, Mariotto S, Ferrari S, Calabrese M, Zanusso G, Gajofatto A, Sansonno D, Dammacco F. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. *World J Gastroenterol*. 2015 Nov 14;21(42):11974-83 (IF: 2.369; JCR 2014)
28. Gajofatto A, Turatti M, Monaco S, Benedetti MD. MMMMMClinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. *Drug Healthc Patient Saf*. 2015 Dec 11;7:157-67
29. Patti F, Messina S., Amato M.P., Bergamaschi R., Bertolotto A., Bonavita S., Bruno Bossio R., Brescia Morra V., Costantino G.F., Cavalla P., Centonze D., Comi G., Cottone S., Danni M., Francia A., Gajofatto A., et al. A multicenter, observational study to evaluate the THC:CBD oromucosal spray (Sativex®) effects in la large population of Multiple Sclerosis patients: SA.FE. study, an Italian Experience. *J Neurol Neurosurg Psychiatry* 2016;87(9):944-51
30. Gajofatto A. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. *Mult Scler Relat Disord*. 2016;8:64-5
31. Calabrese M, Castellaro M, Bertoldo A, De Luca A, Pizzini FB, Ricciardi GK, Pitteri M, Zimatore S, Magliozzi R, Benedetti MD, Manganotti P, Montemezzi S, Reynolds R, Gajofatto A, Monaco S. Epilepsy in multiple sclerosis: The role of temporal lobe damage. *Mult Scler*. 2017 Mar;23(3):473-482
32. Gajofatto A, Turatti M, Benedetti MD. Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. *Expert Rev Neurother*. 2017 Apr;17(4):393-406
33. Turri G, Calabrese M, Pancheri E, Monaco S, Gajofatto A, Marafioti V. QTc interval in patients with multiple sclerosis: an inference from the insula of Reil? *Eur J Neurol*. 2017 Mar;24(3):491-496
34. Farina G, Magliozzi R, Pitteri M, Reynolds R, Rossi S, Gajofatto A, Benedetti MD, Facchiano F, Monaco S, Calabrese M. Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. *J Neuroinflammation*. 2017 Feb 21;14(1):40
35. Ferraro D, Franciotta D, Bedin R, Solaro C, Cocco E, Santangelo M, Immovilli P, Gajofatto A, Calabrese M, Di Filippo M, Orlandi R, Simone AM, Vitetta F, Capello E, Giunti D, Murialdo A, Frau J, Mariotto S, Gallina A, Gasperini C, Sola P; RIREMS group. A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. *J Neurol*. 2017 May;264(5):973-978
36. Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, et al. Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). *PLoS One*. 2017 Aug 1;12(8):e0180651
37. Gajofatto A, Nourbakhsh B, Benedetti MD, Waubant E. Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2017 Sep 22 [Epub ahead of print]

38. Gobbin F, Marangi A, Orlandi R, Richelli S, Turatti M, Calabrese M, Forgione A, Alessandrini F, Benedetti MD, Monaco S, Gajofatto A. A case of acute fulminant multiple sclerosis treated with alemtuzumab. *Mult Scler Relat Disord*. 2017 Oct;17:9-11
39. Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, Farinazzo A, Capra R, Mancinelli C, De Rossi N, Bombardi R, Zuliani L, Zoccarato M, Tanel R, Bonora A, Turatti M, Calabrese M, Polo A, Pavone A, Grazian L, Sechi G, Sechi E, Urso D, Delogu R, Janes F, Deotto L, Cadaldini M, Bianchi MR, Cantalupo G, Reindl M, Gajofatto A. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. *J Neurol*. 2017 Dec;264(12):2420-2430
40. Gajofatto A. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. *Drug Des Devel Ther*. 2017 Nov 2;11:3153-3157
41. Marangi A, Gajofatto A, Marastoni D, Gobbin F, Guiotto F, Tonin P, Benedetti MD. A case of multiple sclerosis and necrotizing autoimmune myopathy with anti-SRP antibodies. *Mult Scler Relat Disord*. 2017 Nov 23;19:118-120
42. Arru G, Sechi E, Mariotto S, Farinazzo A, Mancinelli C, Alberti D, Ferrari S, Gajofatto A, Capra R, Monaco S, Deiana GA, Caggiu E, Mamei G, Sechi LA, Pietro Sechi G. Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. *Mult Scler J Exp Transl Clin*. 2017 Nov 22;3(4):2055217317742425
43. Mariotto S, Farinazzo A, Monaco S, Gajofatto A, et al. Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status. *Mult Scler J Exp Transl Clin*. 2017 Nov 22;3(4):2055217317743098
44. Gajofatto A, Turatti M. Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis. *Expert Opin Investig Drugs*. 2018 Feb 23:1-14. doi: 10.1080/13543784.2018.1442437. [Epub ahead of print]
45. Bo M, Arru G, Sechi E, Niegowska M, Mariotto S, Mancinelli C, Farinazzo A, Alberti D, Gajofatto A, et al. Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. *J Neuroimmunol*. 2018;318:97-102
46. Magliozzi R, Howell OW, Nicholas R, Cruciani C, Castellaro M, Romualdi C, Rossi S, Pitteri M, Benedetti MD, Gajofatto A, Pizzini FB, Montemezzi S, Rasia S, Capra R, Bertoldo A, Facchiano F, Monaco S, Reynolds R, Calabrese M. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. *Ann Neurol*. 2018 Mar 8. doi: 10.1002/ana.25197. [Epub ahead of print]
47. Bacchin R, Macchione F, Cardellini D, Orlandi R, Gajofatto A, Zanusso G, Vattemi G. Levofloxacin-induced hemichorea-hemiballism in a patient with previous thalamic infarction. *Neurol Sci*. 2018 Mar 6. doi: 10.1007/s10072-018-3298-1. [Epub ahead of print]
48. Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttarì F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group. A multicentRE observational analysis of PERSISTENCE to Treatment in the new multiple sclerosis era: the RESPECT study. *J Neurol*. 2018 Mar 16. doi: 10.1007/s00415-018-8831-x. [Epub ahead of print]
49. Benedetti MD, Marangi A, Bozzetti S, Gobbin F, Turatti M, Pea M, Gajofatto A, Mocella S. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod. *Mult Scler Relat Disord*. 2018 Jul;23:24-26. doi: 10.1016/j.msard.2018.04.018. Epub 2018 May 2.
50. Baldin E, Riise T, Mattarozzi K, Gajofatto A, Granella F, Leone M, Lugaesi A, Malagù S, Motti L, Neri W, Pesci I, Santangelo M, Scandellari C, Tola MR, Vignatelli L, Zenesini C, D'Alessandro R; G.E.Ro.N.I.Mu.S. study group. Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis. *Neurol Sci*. 2018 Sep 25. doi: 10.1007/s10072-018-3582-0. [Epub ahead of print]
51. Gandolfi M, Valè N, Dimitrova EK, Mazzoleni S, Battini E, Benedetti MD, Gajofatto A, Ferraro F, Castelli M, Camin M, Filippetti M, De Paoli C, Chemello E, Picelli A, Corradi J, Waldner A, Saltuari L, Smânia N. Effects of High-intensity Robot-assisted Hand Training on Upper Limb Recovery and Muscle Activity in Individuals With Multiple Sclerosis: A Randomized, Controlled, Single-Blinded Trial. *Front Neurol*. 2018 Oct 24;9:905. doi: 10.3389/fneur.2018.00905. eCollection 2018.
52. Gobbin F, Zanoni M, Marangi A, Orlandi R, Crestani L, Benedetti MD, Gajofatto A. 2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity? *Mult Scler Relat Disord*. 2019 Apr;29:23-25.

<https://www.ncbi.nlm.nih.gov/pubmed/?term=gajofatto+a>

Awards

- Young Investigator Award for Multiple Sclerosis Research 2013; European Charcot Foundation 21st Annual Meeting; Baveno, Italy, 28-30 November 2013
- Neuroimmunology and Demyelinating Diseases Special Interest Group; American Neurological Association 134th Annual Meeting; Baltimore, MD, October 2009

Citation Overview

Number of cited documents: 50  
Total number of citations: 648  
H-Index: 14  
(source: Scopus, accessed on March 31, 2019)